The disrupter effect seems quite weak. Their comparator is omalizumab, which is not a potent disrupter itself. Some AI will tell you omalizumab is a disrupter, but it really is a blocker because it blocks binding of IgE to its receptor in the first place. That's quite different. IgE disrupters are known in general. The challenge is not finding an IgE disrupter, but finding one that is "human" enough to work as a chronic treatment. [Edit to add:] https://pmc.ncbi.nlm.nih.gov/articles/PMC8502201/